Differentiation as a CDO
First written in FY2016. 26 of 29 entries say "Restated". Latest entry: 2026-06-10.
1 other company's latest entry also says "Advanced".
- 2026-06-10AdvancedEarnings presentation
「グローバルワンストップのCROサービスと、ニーズにあわせたきめ細かいソリューション提案を組み合わせ、大手グローバルCROと差別化」
ＣＤＯ・グローバルＣＲＯとしての差別化について、ワンストップサービスと個別提案を組み合わせる具体的な方法が示された。 - FY2026-H1RestatedAnnual report
「There has been no material change in the current status or outlook of our group's management strategy during the interim consolidated accounting period.」
The Company states that there has been no material change in its previous policy of pursuing the CDO model and differentiating itself through selectivity and concentration in contract services. - FY2025-H1RestatedAnnual report
「Our group will continue to differentiate itself from existing CROs by pursuing selectivity and concentration in its contract services. We aim to become a CRO, or a CDO (Contract Development Organization), with the knowledge, technology and experience to execute and support pharmaceutical development on an equal footing with major pharmaceutical companies.」
The previous policy of pursuing the CDO model and differentiating the Company from existing CROs through selectivity and concentration in contract services remains in place. - FY2024ReframedAnnual report
「We focus on specific disease areas with high unmet medical needs and high development difficulty, including oncology, central nervous system disorders and immune diseases. We aim to become a global CRO originating in Japan, with the knowledge, technology and experience to execute and support pharmaceutical development on an equal footing with major pharmaceutical companies. To achieve further growth, our medium-term management vision established in 2022 sets out the goal of becoming a strategic partner to clients as a global CRO originating in Japan.」
In addition to the previous description of differentiation as a CDO, the Company has established “a strategic partner to clients” as its medium-term management vision and repositioned itself as a global CRO originating in Japan. - FY2024-Q3RestatedAnnual report
「There has been no material change in the current status or outlook of our group's management strategy during the first nine months of the fiscal year. Our group will continue to differentiate itself from existing CROs by pursuing selectivity and concentration in its contract services. We aim to become a CRO, or a CDO (Contract Development Organization), with the knowledge, technology and experience to execute and support pharmaceutical development on an equal footing with major pharmaceutical companies.」
The Company has reaffirmed that there has been no material change in its positioning of differentiating itself from existing CROs and pursuing the CDO model through selectivity and concentration in contract services. - FY2024-Q2RestatedAnnual report
「There has been no material change in the current status or outlook of our group's management strategy during the first six months of the fiscal year. Our group will continue to differentiate itself from existing CROs by pursuing selectivity and concentration in its contract services. We aim to become a CRO, or a CDO (Contract Development Organization), with the knowledge, technology and experience to execute and support pharmaceutical development on an equal footing with major pharmaceutical companies.」
The Company has reaffirmed that there has been no material change in its positioning of pursuing the CDO model and differentiating itself from existing CROs through selectivity and concentration in contract services. - FY2024-Q1RestatedAnnual report
「There has been no material change in the current status or outlook of our group's management strategy during the first three months of the fiscal year. Our group will continue to differentiate itself from existing CROs by pursuing selectivity and concentration in its contract services. We aim to become a CRO, or a CDO (Contract Development Organization), with the knowledge, technology and experience to execute and support pharmaceutical development on an equal footing with major pharmaceutical companies.」
The Company has reaffirmed that there has been no material change in its positioning of differentiating itself from existing CROs and pursuing the CDO model through selectivity and concentration in contract services. - FY2023-Q2RestatedAnnual report
「There has been no material change in the current status or outlook of our group's management strategy during the first six months of the fiscal year. Our group will continue to differentiate itself from existing CROs by pursuing selectivity and concentration in its contract services. We aim to become a CRO, or a CDO (Contract Development Organization), with the knowledge, technology and experience to execute and support pharmaceutical development on an equal footing with major pharmaceutical companies.」
The Company has reaffirmed that there has been no material change in its policy of pursuing the CDO model and differentiating itself from existing CROs through selectivity and concentration in contract services. - FY2023-Q1RestatedAnnual report
「Our group will continue to differentiate itself from existing CROs by pursuing selectivity and concentration in its contract services. We aim to become a CRO, or a CDO (Contract Development Organization), with the knowledge, technology and experience to execute and support pharmaceutical development on an equal footing with major pharmaceutical companies.」
There has been no material change in the policy of pursuing the CDO model and differentiating the Company by executing and supporting pharmaceutical development on an equal footing with major pharmaceutical companies. - FY2022-Q3RestatedAnnual report
「Our group will continue to differentiate itself from existing CROs by pursuing selectivity and concentration in its contract services. We aim to become a CRO, or a CDO (Contract Development Organization), with the knowledge, technology and experience to execute and support pharmaceutical development on an equal footing with major pharmaceutical companies.」
There has been no material change in the policy of differentiating the Company from existing CROs through selectivity and concentration in contract services and pursuing the CDO model. - FY2022-Q2RestatedAnnual report
「Our group will continue to differentiate itself from existing CROs by pursuing selectivity and concentration in its contract services. We aim to become a CRO, or a CDO (Contract Development Organization), with the knowledge, technology and experience to execute and support pharmaceutical development on an equal footing with major pharmaceutical companies.」
There has been no material change in the positioning of pursuing the CDO model and executing and supporting pharmaceutical development on an equal footing with major pharmaceutical companies. - FY2021-Q3RestatedAnnual report
「Our group will continue to differentiate itself from existing CROs by pursuing selectivity and concentration in its contract services. We aim to become a CRO, or a CDO (Contract Development Organization), with the knowledge, technology and experience to execute and support pharmaceutical development on an equal footing with major pharmaceutical companies.」
The positioning of pursuing the CDO model and executing and supporting pharmaceutical development on an equal footing with major pharmaceutical companies remains in place. - FY2021-Q2RestatedAnnual report
「Our group will continue to differentiate itself from existing CROs by pursuing selectivity and concentration in its contract services. We aim to become a CRO, or a CDO (Contract Development Organization), with the knowledge, technology and experience to execute and support pharmaceutical development on an equal footing with major pharmaceutical companies.」
The positioning of pursuing the CDO model and supporting development on an equal footing with major pharmaceutical companies remains in place. - FY2021-Q1RestatedAnnual report
「Our group will continue to differentiate itself from existing CROs by pursuing selectivity and concentration in its contract services. We aim to become a CRO, or a CDO (Contract Development Organization), with the knowledge, technology and experience to execute and support pharmaceutical development on an equal footing with major pharmaceutical companies.」
The positioning of pursuing a CDO capable of executing and supporting pharmaceutical development on an equal footing with major pharmaceutical companies remains in place. - FY2020RestatedAnnual report
「Our group focuses on specific areas, contract services and clinical trial stages, and refers to a CRO with the knowledge, technology and experience to execute and support pharmaceutical development on an equal footing with major pharmaceutical companies as a CDO (Contract Development Organization).」
The positioning of pursuing a CDO that focuses on specific areas, services and clinical trial stages and supports development on an equal footing with major pharmaceutical companies remains in place. - FY2020-Q3RestatedAnnual report
「Our group will continue to differentiate itself from existing CROs by pursuing selectivity and concentration in its contract services. We aim to become a CRO, or a CDO (Contract Development Organization), with the knowledge, technology and experience to execute and support pharmaceutical development on an equal footing with major pharmaceutical companies.」
The policy of pursuing the CDO model and executing and supporting development on an equal footing with major pharmaceutical companies remains in place. - FY2020-Q1RestatedAnnual report
「Our group will continue to differentiate itself from existing CROs by pursuing selectivity and concentration in its contract services. We aim to become a CRO, or a CDO (Contract Development Organization), with the knowledge, technology and experience to execute and support pharmaceutical development on an equal footing with major pharmaceutical companies.」
The positioning of pursuing the CDO model and executing and supporting pharmaceutical development on an equal footing with major pharmaceutical companies remains in place. - FY2019-Q3RestatedAnnual report
「Our group will continue to differentiate itself from existing CROs by pursuing selectivity and concentration in its contract services. We aim to become a CRO, or a CDO (Contract Development Organization), with the knowledge, technology and experience to execute and support pharmaceutical development on an equal footing with major pharmaceutical companies.」
The policy of pursuing a CDO capable of executing and supporting pharmaceutical development on an equal footing with major pharmaceutical companies remains in place. - FY2019-Q2RestatedAnnual report
「Our group will continue to differentiate itself from existing CROs by pursuing selectivity and concentration in its contract services. We aim to become a CRO, or a CDO (Contract Development Organization), with the knowledge, technology and experience to execute and support pharmaceutical development on an equal footing with major pharmaceutical companies.」
The policy of pursuing a CDO capable of executing and supporting pharmaceutical development on an equal footing with major pharmaceutical companies remains in place. - FY2019-Q1RestatedAnnual report
「Our group will continue to differentiate itself from existing CROs by pursuing selectivity and concentration in its contract services. We aim to become a CRO, or a CDO (Contract Development Organization), with the knowledge, technology and experience to execute and support pharmaceutical development on an equal footing with major pharmaceutical companies.」
The policy of pursuing a CDO capable of executing and supporting pharmaceutical development on an equal footing with major pharmaceutical companies remains in place. - FY2018RestatedAnnual report
「To meet the requirements of the pharmaceutical companies described above, our group is differentiating itself from other companies in the industry by developing its core CRO business toward becoming a CDO specializing primarily in monitoring during Phase II and Phase III, the principal stages of clinical trials, together with related quality control and consulting services.」
The policy of differentiating the Company as a CDO specializing in monitoring, quality control and consulting for Phase II and Phase III has been reaffirmed. - FY2018-Q3RestatedAnnual report
「Our group will continue to differentiate itself from existing CROs by pursuing selectivity and concentration in its contract services. We aim to become a CRO, or a CDO (Contract Development Organization), with the knowledge, technology and experience to execute and support pharmaceutical development on an equal footing with major pharmaceutical companies.」
The positioning of pursuing the CDO model and executing and supporting pharmaceutical development on an equal footing with major pharmaceutical companies remains in place. - FY2018-Q2RestatedAnnual report
「Our group will continue to differentiate itself from existing CROs by pursuing selectivity and concentration in its contract services. We aim to become a CRO, or a CDO (Contract Development Organization), with the knowledge, technology and experience to execute and support pharmaceutical development on an equal footing with major Japanese pharmaceutical companies.」
The policy of pursuing a CDO capable of executing and supporting pharmaceutical development on an equal footing with major Japanese pharmaceutical companies remains in place. - FY2018-Q1RestatedAnnual report
「Our group will continue to differentiate itself from existing CROs by pursuing selectivity and concentration in its contract services. We aim to become a CRO, or a CDO (Contract Development Organization), with the knowledge, technology and experience to execute and support pharmaceutical development on an equal footing with major pharmaceutical companies.」
The policy of pursuing the CDO model and executing and supporting pharmaceutical development on an equal footing with major pharmaceutical companies remains in place. - FY2017RestatedAnnual report
「To meet the requirements of the pharmaceutical companies described above, our group is differentiating itself from other companies in the industry by developing its core CRO business toward becoming a CDO specializing in monitoring during Phase II and Phase III, the principal stages of clinical trials, together with related quality control and consulting services.」
The positioning of pursuing a CDO specializing in monitoring and related services for Phase II and Phase III and differentiating the Company from other companies in the industry remains in place. - FY2017-Q3RestatedAnnual report
「Our group will continue to differentiate itself from existing CROs by pursuing selectivity and concentration in its contract services. We aim to become a CRO, or a CDO (Contract Development Organization), with the knowledge, technology and experience to execute and support pharmaceutical development on an equal footing with major pharmaceutical companies.」
The positioning of pursuing the CDO model and supporting pharmaceutical development on an equal footing with major pharmaceutical companies remains in place. - FY2017-Q2RestatedAnnual report
「Our group will continue to differentiate itself from existing CROs by pursuing selectivity and concentration in its contract services. We aim to become a CRO, or a CDO (Contract Development Organization), with the knowledge, technology and experience to execute and support pharmaceutical development on an equal footing with major Japanese pharmaceutical companies.」
The positioning of pursuing the CDO model and supporting development on an equal footing with major Japanese pharmaceutical companies remains in place. - FY2017-Q1RestatedAnnual report
「Our group will continue to differentiate itself from existing CROs by pursuing selectivity and concentration in its contract services. We aim to become a CRO, or a CDO (Contract Development Organization), with the knowledge, technology and experience to execute and support pharmaceutical development on an equal footing with major pharmaceutical companies.」
The policy of pursuing the CDO model and differentiating the Company by supporting development on an equal footing with major pharmaceutical companies remains in place. - FY2016First statedAnnual report
「To meet the requirements of the pharmaceutical companies described above, our group is differentiating itself from other companies in the industry by developing its core CRO business toward becoming a CDO specializing in monitoring during Phase II and Phase III, the principal stages of clinical trials, together with related quality control and consulting services.」
The Company positions itself as pursuing a CDO capable of supporting development on an equal footing with major pharmaceutical companies.